Patients with two forms of leukemia, who currently have no viable treatment options, may benefit from existing drugs developed for different types of cancer, according to a study conducted by researchers at the Knight Cancer Institute at Oregon Health & Science University. The study, published in the New England Journal of Medicine, isolated the molecular mutation that causes chronic neutrophilic leukemia and atypical chronic myeloid leukemia in some patients. Read more here.
Study mentioned: Maxson JE, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013 May 9;368(19):1781-90. PMID: 23656643
No comments:
Post a Comment